Qiagen (NYSE:QGEN) Issues Q3 2026 Earnings Guidance

Qiagen (NYSE:QGEN) issued an update on its third quarter 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 0.620- for the period, compared to the consensus earnings per share estimate of 0.630. The company issued revenue guidance of $538.3 million-$543.7 million, compared to the consensus revenue estimate of $552.7 million.

Qiagen Price Performance

Shares of NYSE:QGEN opened at $42.28 on Friday. The company’s fifty day moving average is $39.43 and its 200 day moving average is $41.69. The company has a quick ratio of 2.57, a current ratio of 3.21 and a debt-to-equity ratio of 0.49. Qiagen has a 52 week low of $32.53 and a 52 week high of $57.81. The stock has a market cap of $8.71 billion, a PE ratio of 21.66, a PEG ratio of 4.16 and a beta of 0.63.

Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.60 by $0.02. The firm had revenue of $535.04 million for the quarter, compared to analysts’ expectations of $527.50 million. Qiagen had a return on equity of 14.24% and a net margin of 19.49%.The company’s revenue for the quarter was up .2% compared to the same quarter last year. During the same period last year, the firm earned $0.60 earnings per share. Qiagen has set its FY 2026 guidance at 2.430- EPS. Research analysts anticipate that Qiagen will post 2.43 earnings per share for the current year.

Qiagen Increases Dividend

The business also recently declared an annual dividend, which was paid on Tuesday, July 14th. Investors of record on Tuesday, July 7th were given a dividend of $0.35 per share. This represents a yield of 90.0%. The ex-dividend date was Tuesday, July 7th. This is a positive change from Qiagen’s previous annual dividend of $0.26. Qiagen’s dividend payout ratio is 18.32%.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Robert W. Baird set a $43.00 price target on Qiagen and gave the stock an “outperform” rating in a research note on Wednesday, April 29th. Jefferies Financial Group reissued a “buy” rating and issued a $48.00 price target on shares of Qiagen in a report on Thursday. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $43.00 price objective on shares of Qiagen in a research report on Thursday, April 30th. Stifel Nicolaus set a $40.00 price objective on shares of Qiagen in a research note on Friday. Finally, Kepler Capital Markets set a $38.60 target price on shares of Qiagen and gave the stock a “hold” rating in a report on Thursday, June 25th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $43.34.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Danske Bank A S bought a new stake in shares of Qiagen during the 3rd quarter valued at about $36,000. Global Retirement Partners LLC raised its stake in Qiagen by 279.9% in the fourth quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock worth $52,000 after buying an additional 851 shares in the last quarter. Advisory Services Network LLC bought a new position in Qiagen in the third quarter worth about $64,000. Kestra Advisory Services LLC bought a new position in Qiagen in the fourth quarter worth about $70,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in Qiagen in the fourth quarter worth about $73,000. 70.00% of the stock is currently owned by institutional investors.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.